Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• TD Cowen Upgrades Targa Resources (TRGP) to Buy, 'Wet Gas Fuels Growth'
• TD Cowen Reiterates Buy Rating on Brinker Int'l (EAT)
• Jefferies Downgrades Fluence Energy Inc. (FLNC) to Hold